Cargando…
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
BACKGROUND: Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor th...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407785/ https://www.ncbi.nlm.nih.gov/pubmed/22559819 http://dx.doi.org/10.1186/1756-8722-5-20 |